Indivior Pharmaceuticals, Inc.（INDV）適時開示・決算発表
今後の予定
- 2026-10-29 決算発表 推定
| 提出日 | 様式 | 項目 | 原文 |
|---|---|---|---|
| 2026-08-03 | 8-K | 重要契約の締結、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2026-08-03 | 8-K | 決算発表、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2026-08-03 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2026-05-15 | 8-K | 役員の異動、株主総会の議決結果 | SEC |
| 2026-05-04 | 8-K | Reg FD 開示、その他の事項、財務諸表・添付書類 | SEC |
| 2026-04-30 | 8-K | 決算発表、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2026-03-17 | 8-K | 重要契約の締結、契約の終了、直接的な財務義務、未登録株式の売出、財務諸表・添付書類 | SEC |
| 2026-03-13 | 8-K | その他の事項、財務諸表・添付書類 | SEC |
| 2026-03-12 | 8-K | その他の事項、財務諸表・添付書類 | SEC |
| 2026-02-26 | 8-K | 決算発表、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2026-01-26 | 8-K | 重要契約の締結、直接的な財務義務、未登録株式の売出、Item 3.03、支配権の変更、役員の異動、定款変更、Item 5.05、Reg FD 開示、その他の事項、財務諸表・添付書類 | SEC |
| 2026-01-08 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-12-22 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-12-18 | 8-K | 役員の異動 | SEC |
| 2025-12-15 | 8-K | 定款変更、株主総会の議決結果、財務諸表・添付書類 | SEC |
| 2025-11-20 | 8-K | 契約の終了、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-11-14 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-10-30 | 8-K | 決算発表、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-10-01 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-08-26 | 8-K | Item 2.05 | SEC |
| 2025-08-22 | 8-K | 役員の異動、財務諸表・添付書類 | SEC |
| 2025-07-31 | 8-K | 決算発表、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-06-30 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-06-24 | 8-K | 役員の異動、その他の事項、財務諸表・添付書類 | SEC |
| 2025-06-02 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-06-02 | 8-K | その他の事項、財務諸表・添付書類 | SEC |
| 2025-05-08 | 8-K | 役員の異動、定款変更、株主総会の議決結果、Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-04-24 | 8-K | 決算発表、財務諸表・添付書類 | SEC |
| 2025-03-27 | 8-K | Reg FD 開示、財務諸表・添付書類 | SEC |
| 2025-03-04 | 8-K | 重要契約の締結、役員の異動、財務諸表・添付書類 | SEC |
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-02-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | JOSEPH CIAFFONI APPOINTED CHIEF EXECUTIVE OFFICER | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-27 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2025-02-25 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-02-24 | 6-K | FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-20 | 6-K | — | SEC |
| 2025-02-12 | 6-K | DELAYED FDA APPROVAL OF SUBLOCADE LABEL CHANGES | SEC |
| 2025-02-04 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-02-04 | 6-K | COMPLETION OF SHARE REPURCHASE PROGRAM | SEC |
| 2025-02-04 | 6-K | NOTICE OF RESULTS | SEC |
| 2025-02-03 | 6-K | APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR | SEC |
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2025-01-28 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-28 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-28 | 6-K | DR. DAVID WHEADON APPOINTED CHAIR OF THE BOARD | SEC |
| 2025-01-27 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-21 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-14 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-10 | 6-K | INDIVIOR PROVIDES HISTORICAL FINANCIALS IN US GAAP | SEC |
| 2025-01-07 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2025-01-07 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2024-12-31 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-31 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2024-12-26 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2024-12-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
出典は SEC EDGAR の 8-K／6-K。8-K は米国内企業の臨時報告（Item 2.02 が決算発表）、6-K は外国企業（ADR 含む）の対応様式です。当サイトはリンクの整理のみ行い、原文はすべて sec.gov にあります。